CHARGED ALPHATMFrontier AI stock research

DGX · NYSE

Quest Diagnostics Incorporated

Diagnostics & Research · United States

USD 229.59-0.8% daily changeQuote 2026-10-06 · USD
Market cap (USD)
US$25.34B
Trailing P/E
24.37x
Forward P/E
19.04x
Quarterly revenue growth
10.2%
Trailing net margin
9.2%
Indicated dividend yield
1.5%

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Next earnings: 2026-10-22 (provider estimate, not issuer-confirmed).

Company background

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Company website

Q2 2026

Go beyond the headline.

Quest Diagnostics Stock (DGX): It Beat, RAISED Guidance, and Broke Out — Why We Say BUY

Published 2026-07-24

Comparable businesses

DGX peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

Market metrics · missing or inapplicable values shown as —
MetricDGXQuest Diagnostics IncorporatedSnapshot 2026-10-06Financial period: 2026-06-30LHLabcorp Holdings Inc.Snapshot 2026-10-06Financial period: 2026-06-30MTDMettler-Toledo International Inc.Snapshot 2026-10-06Financial period: 2026-06-30Peer medianSimilar-size peers only
Market capMarket value, converted to USDUS$25.34BUS$25.24BUS$31.31BUS$28.28Bn=2
Forward P/EProvider forward earnings estimate19.04x15.69x30.20x22.95xn=2
EV / EBITDAEnterprise value / trailing EBITDA14.03x13.68x25.85x19.76xn=2
Revenue growthLatest quarter vs prior-year quarter10.2%5.8%4.5%5.2%n=2
Operating marginLatest reported quarter15.2%12.2%31.2%21.7%n=2
Free cash flow yieldTrailing cash flow / market cap3.6%3.5%2.2%2.9%n=2
Net debt / EBITDANet debt / trailing EBITDA2.55x2.88x1.64x2.26xn=2
Debt / equityTotal debt / positive book equity0.81x0.79x166.68x83.74xn=2
Trailing P/ETrailing twelve-month earnings24.37x25.73x35.22x30.47xn=2
Price / bookPrice / positive book equity per share3.36x2.93x2,441.41x1,222.17xn=2
EV / salesEnterprise value / trailing revenue2.75x2.21x7.98x5.09xn=2
Earnings growthLatest quarter vs prior-year quarter15.0%28.2%18.3%23.2%n=2
Gross marginTrailing twelve months33.2%28.9%60.3%44.6%n=2
Net marginTrailing twelve months9.2%7.0%21.9%14.4%n=2
Return on equityProvider trailing return; positive equity only14.6%11.7%——
Free cash flow marginTrailing free cash flow / revenue7.9%6.2%16.8%11.5%n=2
Dividend yieldIndicated annual dividend / price1.5%0.9%——
Earnings payoutProvider trailing dividend payout26.1%23.8%0.0%11.9%n=2
Current ratioCurrent assets / current liabilities1.59x1.80x1.12x1.46xn=2
BetaProvider historical market sensitivity0.540.851.191.02n=2

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for DGX

All available reporting periods
Q2 20262026-07-24
Q1 20262026-04-22
Deep Dive2026-04-22

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.